TOPOTECAN-D6
TOPOTECAN-D6 Basic information
- Product Name:
- TOPOTECAN-D6
- Synonyms:
-
- TOPOTECAN-D6
- (4S)-10-[[Di(methyl-d3)amino]methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[346-7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
- SKF-104864A-d6
- (4S)-10-[(Dimethylamino-d6)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3’,4’,6-7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
- Hycamtin-d6
- NSC-609669-d6
- (4S)-10-[[Di(methyl-d3)amino]methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
- [2H6]-Topotecan
- CAS:
- 1044904-10-0
- MF:
- C23H23N3O5
- MW:
- 421.45
- Product Categories:
-
- Heterocycles
- Isotope Labelled Compounds
- Inhibitors
- Intermediates & Fine Chemicals
- Isotope Labeled Compounds
- Pharmaceuticals
- Mol File:
- 1044904-10-0.mol
TOPOTECAN-D6 Chemical Properties
- Melting point:
- 213-218°C (dec)
- storage temp.
- -20°C Freezer
- solubility
- aqueous acid: soluble; DMSO: slightly; Methanol: soluble
- form
- A solid
- color
- Light yellow to yellow
- Stability:
- Hygroscopic
- CAS DataBase Reference
- 1044904-10-0
TOPOTECAN-D6 Usage And Synthesis
Description
Topotecan-d6 is intended for use as an internal standard for the quantification of topotecan by GC- or LC-MS. Topotecan is an inhibitor of DNA topoisomerase I and a derivative of the DNA topoisomerase I inhibitor camptothecin . Topotecan inhibits DNA topoisomerase I in human MCF-7 breast and DU145 prostate cancer cells with IC50 values of 13 and 2 nM, respectively, in a cell-based luciferase reporter assay. Topotecan induces cytotoxicity and DNA damage in HT-29 human colon adenocarcinoma cells (IC50s = 33 and 280 nM, respectively). Formulations containing topotecan have been used in the treatment of small-cell lung cancer.
Chemical Properties
Light Yellow to Greenish Powder
Uses
Labelled Topotecan. A DNA topoisomerase I inhibitor; semisynthetic analog of Camptothecin. Antineoplastic
Uses
Labelled Topotecan (T542500). A DNA topoisomerase I inhibitor; semisynthetic analog of Camptothecin. Antineoplastic.
References
[1] ROTHENBERG M L. Topoisomerase I inhibitors: Review and update[J]. Annals of Oncology, 1997, 8 9: Pages 837-855. DOI: 10.1023/a:1008270717294
[2] J DANCEY EA E. Current perspectives on camptothecins in cancer treatment[J]. British Journal of Cancer, 1996, 74 3: 327-338. DOI: 10.1038/bjc.1996.362
[3] JHM SCHELLENS. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor[J]. British Journal of Cancer, 1996, 73 10: 1268-1271. DOI: 10.1038/bjc.1996.243
[4] GISELA CACERES. Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors.[J]. Anti-Cancer Drugs, 2003, 14 7: 569-574. DOI: 10.1097/00001813-200308000-00010
TOPOTECAN-D6Supplier
- Tel
- 18210857532; 18210857532
- jkinfo@jkchemical.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 021-65675885 18964387627
- info@efebio.com
- Tel
- 0755-85201366 18938635012
- sales@regentsciences.com
- Tel
- 400-9205774
- sales@glpbio.cn